APA (7th ed.) Citation

Shiri, P., Ramezanpour, S., Amani, A. M., & Dehaen, W. (2022). A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. Molecular diversity, 26(5), 2981-3002. https://doi.org/10.1007/s11030-022-10406-8

Chicago Style (17th ed.) Citation

Shiri, Pezhman, Sorour Ramezanpour, Ali Mohammad Amani, and Wim Dehaen. "A Patent Review on Efficient Strategies for the Total Synthesis of Pazopanib, Regorafenib and Lenvatinib as Novel Anti-angiogenesis Receptor Tyrosine Kinase Inhibitors for Cancer Therapy." Molecular Diversity 26, no. 5 (2022): 2981-3002. https://doi.org/10.1007/s11030-022-10406-8.

MLA (9th ed.) Citation

Shiri, Pezhman, et al. "A Patent Review on Efficient Strategies for the Total Synthesis of Pazopanib, Regorafenib and Lenvatinib as Novel Anti-angiogenesis Receptor Tyrosine Kinase Inhibitors for Cancer Therapy." Molecular Diversity, vol. 26, no. 5, 2022, pp. 2981-3002, https://doi.org/10.1007/s11030-022-10406-8.